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A Promoter Sequence Variant of ZNF750 Is Linked
with Familial Psoriasis
Chi-Fan Yang1,2, Wuh-Liang Hwu3,4, Li-Cheng Yang5, Wen-Hung Chung2,5, Yin-Hsiu Chien3,4,
Chia-Fu Hung2, Hung-Chih Chen2, Pei-Joung Tsai2, Cathy S.J. Fann2, Fang Liao2 and Yuan-Tsong Chen2,6
We previously mapped a psoriasis-susceptibility gene to a 3.8-Mb region of the 17q terminus in a five-
generation Chinese family with autosomal-dominant psoriasis. To identify the mutations responsible for the
psoriasis in this family, we sequenced 78 genes within the region and found four gene variants, p.Ala201Val in
CD7, c.625A4C in zinc-finger protein 750 (ZNF750), p.Asp189Asn in C17orf56, and p.Ala568Thr in AATK
cosegregated with the disease. The latter two variants were not studied further in the absence of disease
segregation in other familial psoriasis and presence of variants in normal subjects. Functional analyses of CD7
did not support CD7 as a disease-causing gene. In contrast, the c.625A4C mutation in ZNF750 resulted in a
42% reduction of the promoter activity, and the electrophoretic mobility shift assay showed binding of nuclear
protein(s) to the mutant C allele. The c.625A4C mutation was found in another sporadic psoriasis patient but
was absent in 188 normal controls. Together, the mutation accounts for 1.7% (confidence interval: 0.2–5.84%) of
psoriasis in the Chinese population. This report suggests that ZNF750 mutations could contribute to psoriasis
susceptibility.
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INTRODUCTION
Psoriasis is a chronic inflammatory disorder of the skin, nails,
scalp, and joints, which varies in severity and clinical
manifestation. The most common form, plaque psoriasis,
affects 2–3% of the Caucasian population (Lebwohl, 2003)
but only 0.3% of the Mongoloid population (Yip, 1984). The
skin lesions present with hyperproliferation and incomplete
differentiation of epidermal keratinocytes, an increase in
dermal capillaries, and marked infiltration of T cells and
neutrophils in the dermis and epidermis. Current evidence
suggests that psoriasis is an immune-mediated disorder and
novel therapies involved in the suppression of the immune
responses, such as the T-cell-targeted agents and tumor
necrosis factor (TNF) inhibitors, have improved the outcome
of the disease (Krueger, 2002; Gottlieb, 2005). However, not
all patients respond to these therapies and the efficacy varies
between psoriasis patients.
A number of genetic studies have been performed to
identify the psoriasis-susceptibility loci. At least nine candi-
date loci have been reported (PSORS1–9) (Bowcock and
Cookson, 2004), indicating that psoriasis is inherited as a
complex trait with several genes involved and that it can be
influenced by environmental factors. Except for the most
repeatedly mapped HLA class I region (PSORS1), many
groups, including our own, have demonstrated linkage or
association of familial psoriasis to a locus on 17q25 (PSORS2)
(Tomfohrde et al., 1994; Helms et al., 2003; Capon et al.,
2004; Hwu et al., 2005; Stuart et al., 2006). A RUNX1
binding site variant between SLC9A3R1 and NAT9 on
chromosome 17q25 has been identified as a psoriasis-
susceptibility gene from a family-based association study
(Helms et al., 2003). Another locus within the RAPTOR gene
(regulatory associated protein of MTOR) has also been
implicated in psoriasis susceptibility (Helms et al., 2003).
Recently, a gene of unknown function, zinc-finger protein
750 (ZNF750), lying on the distal end of chromosome 17q
was found to associate with a seborrhea-like dermatitis with
psoriasiform elements (Birnbaum et al., 2006). ZNF750
(OMIM# 610226) is a putative member of the zinc-finger
transcription factors with a nuclear localization site at the
50 end and a conserved C2H2 zinc-finger domain. ZNF750 is
expressed in skin, thymus, prostate, lung, and placenta, with
the highest amount in keratinocytes. The skin biopsies of the
patients showed some of the pathological elements seen in
psoriasis, suggesting the involvement of ZNF750 in the
pathogenesis of psoriasis.
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In our previous study of a five-generation extended
psoriasis family, we mapped a psoriasis-susceptibility locus
to a 3.8-Mb region of the chromosome 17q terminus using a
genome-wide scan. Here, we report further investigation of
candidate genes in this region as well as identification and
characterization of sequence variants in two of the candidate
genes in Chinese patients with psoriasis.
RESULTS
Sequence of candidate genes on chromosome 17q terminus
We have previously mapped and narrowed down the
psoriasis-susceptibility locus in our index family to a 3.8-
Mb region between D17S1806 and the 17q terminus of
chromosome 17 (Hwu et al., 2005). This candidate interval
contains 94 genes, including 44 genes of unknown function.
We sequenced 78 genes, including all genes known to be
expressed in skin and/or immune cells as per the HMDEG
(Human and Mouse Differentially Expressed Genes) database
(http://gln.ibms.sinica.edu.tw/product/HMDEG/EST/index.php)
and microarray expression data in the UCSC (University of
California Santa Cruz) database (http://genome.ucsc.edu/). The
remaining 16 genes were not sequenced primarily because
they have (1) limited tissue distribution, such as being
expressed only in the liver, eye, muscle; or (2) housekeeping
genes with mutations resulting in known phenotypes/diseases;
or (3) hypothetical genes with unknown tissue distribution. In
addition, we sequenced for RUNX1 binding site variant
(rs734232, G4A) previously inferred to be psoriasis-suscept-
ibility gene 5Mb proximal to our candidate locus and another
psoriasis-associated single-nucleotide polymorphism (SNP)
(rs869190, G4T) in the raptor gene within our locus on
chromosome 17q. Our proband had G allele present in both
RUNX1 binding site variant and the psoriasis-associated SNP
of the raptor gene.
A total of 22 sequence variants present in the proband, but
not in the normal control, and not found in the dbSNP
databases were subjected to segregation analysis, which
consisted of sequencing all 23 affected members (13 severely
affected and 10 mildly affected) and 16 unaffected members
for the portion of the genes containing variants. Four genes
with sequence variants cosegregated with the disease in our
five-generation index family were identified: they were
p.Ala201Val in the CD7 gene, p.Asp189Asn in the
C17orf56, p.Ala568Thr in the AATK, and c.625A4C in
the ZNF750 gene (Figure 1). To our knowledge, these variants
are all previously unreported. The p.Asp189Asn variant of
C17orf56 and p.Ala568Thr variant of AATK did not segregate
with the disease in other familial psoriasis families (one in
C17orf56 and two in AATK). Furthermore, the allele
frequencies of the two variants in psoriasis patients (2.83%
for C17orf56 and 2.4% for AATK) did not differ from the
controls (1.97% for C17orf56 and 1.09% for AATK) (P¼0.56
and P¼ 0.39 for C17orf56 and AATK, respectively).
Therefore, these two gene variants were not studied further.
The p.Ala201Val variant in CD7 showed complete disease
segregation in familial psoriasis and was present in 1.38%
(3 of 109) of psoriasis patients. However, it was also detected
in two normal individuals (2 of 161 Han Chinese controls,
allele frequency 0.62%) (P¼ 0.4, cases versus controls); one
has atopic dermatitis and the other is allergic to seafood. The
c.625A4C variant of ZNF750 also segregated with the
disease in familial psoriasis and was completely absent in
all 188 normal Han Chinese subjects tested. These data
suggested that CD7 and ZNF750 act as putative genes for
psoriasis in this family. The functional consequences of the
CD7 and ZNF750 mutations were further investigated.
Analysis of the CD7 p.Ala201Val variant
Human CD7 (OMIM# 186820) is a surface membrane-
associated glycoprotein expressed mainly on the surface of
human T and NK cells and, similar to CD28, CD7 acts as a
costimulatory molecule (Stillwell and Bierer, 2001). The
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Figure 1. Schematic representation showing four variants cosegregated with the disease in the family. The position and size of the genes are indicated by
red squares. Nucleotide sequence and amino-acid translation of the patients show heterozygous variation marked by arrows.
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p.Ala201Val mutant identified in the CD7 gene is located in
the predicted transmembrane domain of the CD7 molecule.
To investigate if the mutation could affect the expression of
CD7, we isolated peripheral blood mononuclear cells
(PBMCs) from two patients and five controls and analyzed
the CD7 expression on T and NK cells by using flow
cytometry. The expression level of CD7 and the percentage of
CD7-positive cells in CD4, CD8, or CD56 (NK) cells showed
no difference between patients and controls; a representative
set of data was shown in Figure 2a. We next examined
whether the mutation affects the functionality. We measured
the costimulatory activity of CD7 by evaluating the capability
of cytokine production and T-cell proliferation in response to
anti-CD3 and anti-CD3/CD7 mAb. As expected, cell costi-
mulation with anti-CD7 antibody further increased the
production of IFN-g and TNF-a and proliferation ability as
compared with stimulation with anti-CD3 alone. However,
when compared with normal controls, PBMCs from two
psoriasis patients produced similar levels of IFN-g and TNF-a
and proliferation ability when cultured with anti-CD3 in the
presence or absence of CD7 mAb over a time course of
12, 24, 48, and 72 hours. A representative data set of 48-hour
culture was shown in Figure 2b–d. These data showed
that CD7 is unlikely to be a disease-causing gene.
ZNF750 c.625A4C mutation decreases ZNF750 promoter
activity
The second candidate gene sequence variant identified in the
index family was located 625 bp upstream from the start
codon of the ZNF750 gene (c.625A4C). Alignment of the
50 genomic DNA sequence of ZNF750 from human,
macaque, mouse, opossum, dog, cow, and chicken showed
that the c.625A is conserved in all these species except the
cow (http://www.ebi.ac.uk/Tools/clustalw/index.html). No
other sequence variations of the ZNF750 gene were found
in this family.
Computer searches of transcription factor binding sites
revealed that the c.625A4C substitution eliminated a
potential NF-AT site and introduced overlapping c-Myb and
c-ETS sites. To investigate whether this nucleotide substi-
tution would affect the expression of ZNF750, we con-
structed ZNF750 promoter fragments containing the variant.
We performed the promoter assay in a keratinocyte cell line,
HaCaT, because the highest expression of ZNF750 is in
keratinocytes. The c.625C promoter showed an approxi-
mately 42% decrease in transcriptional activity compared
with the wild-type promoter (Figure 3).
We further investigated whether the downregulation of
ZNF750 by the c.625A4C variant was due to the loss or
gain of transcription factor binding. Electrophoretic mobility
shift assay (EMSA) showed a strong binding of nuclear
protein(s) to the oligonucleotide with the mutant C allele as
compared to the wild-type A allele (Figure 4a, lanes 1–4). This
DNA–protein complex was inhibited in a dose-dependent
manner by the unlabeled mutant C allele, but much less so by
the wild-type A allele (Figure 4a, lanes 5–10), further
suggesting the specificity of nuclear protein(s) binding to
the mutant allele containing C at the c.625 locus.
Competitive assays showed that consensus sequences
recognized by ESE-1, ESE-2, and PU.1 (Figure 4b, lane 2)
competed more efficiently for the DNA–protein complex than
the sequences recognized by other transcription factors,
including PDEF, ETS1, NF-kB, NF-AT, and c-Myb (Figure 4b,
lanes 3–8).
ZNF750 sequence variations in other patients with psoriasis
The c.625A4C variant was not found among the 35 other
familial psoriasis patients but was found in one of the 85
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Figure 2. The effect of p.Ala201Val variant in CD7. (a) Flow cytometric analysis of CD7 expression in gated CD4þ T cells, CD8þ T cells, and
CD56þ NK cells from a representative normal control (upper panel) and his affected brother (lower panel). Histograms show surface fluorescence intensity of
isotype-matched control (empty histogram) and anti-CD7 mAb (filled histogram). The percentage of CD7 expression was indicated. (b, c) PBMC cells from
two patients (P1, P2) and five normal controls (N1–N5) were cultured with anti-CD3 or anti-CD3 plus anti-CD7 in a total volume of 200 ml. The 2-day culture
supernatants were collected and analyzed for production of (b) TNF-a and (c) IFN-g by ELISA. (d) PBMC cells from two patients and five normal controls
were cultured with anti-CD3 or anti-CD3 plus anti-CD7, and cell proliferation was performed by 3H-thymidine uptake.
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sporadic psoriasis patients studied (Table 1). None of the 188
normal subjects contained this mutation. This c.625A4C
variant accounts for 1.7% (2 of 121, confidence interval (CI):
0.2–5.84%) of the psoriasis in the Chinese population.
To further study ZNF750 variations in psoriasis, we
sequenced the ZNF750 gene in 85 sporadic psoriasis patients
as well as 35 additional index patients, each from a family
with familial psoriasis. The same c.625A4C variant was
found in a sporadic psoriasis patient, a c.646G4A variant
in one family with familial psoriasis, a c.597C4T variant in
a sporadic psoriasis patient, and a missense variant of
c.1046T4C (p.Leu349Pro) was detected in another family
with familial psoriasis (Table 1). None of these variants were
found in any of the 188 normal controls. The functional
significance of these variants remained to be investigated.
In addition to the unique sequence variants found only in
psoriasis, a c.1305C4G (p.Asn435Lys) was found in 2
familial psoriasis and 13 sporadic psoriasis cases; however,
this single-nucleotide change is likely to be a polymorphism,
as it was also present in high frequency in normal controls
(6.9%, 13 of 188) (Table 1).
DISCUSSION
In this study, we used the classical positional cloning
approach by sequencing the candidate genes in the 17q
region to identify the responsible gene/mutation for psoriasis
in this unusual five-generation family. Those sequence
variants present in the proband, but not in the normal
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Table 1. Frequency of ZNF750 sequence variants in
affected individuals and normal controls that were
first identified in psoriasis patients
Variants1
Familial
psoriasis
(n=36)
Sporadic
psoriasis
(n=85)
Normal
controls
(n=188)
c.625A4C 1 1 0
c.646G4A 1 0 0
c.597C4T 0 1 0
c.1046T4C (p.L349P) 1 0 0
c.1305C4G (p.N435K) 2 13 13
n, number of individuals; ZNF, zinc-finger protein.
1The ZNF750 cDNA reference sequence used was under GenBank
accession number NM_024702.2. The numbering is based on +1 as the A
of the ATG translation initiation codon.
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Figure 3. The effect of the variations in the promoter region of ZNF750.
The luciferase activity of the reporter constructs containing either the A or
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control, and not found in the dbSNP databases were subjected
to segregation analysis. As only 0.3% of Chinese develop
psoriasis, it is possible that a fully penetrant 17q variation with
minor allele frequencies as high as 1–5% could result in a
disease phenotype. Therefore, we have also performed
segregation analysis in all of the 11 variants found in the
dbSNP database, either with minor allele frequencies o5%
(two variants, 4 and 1.2%) or with unknown frequencies (nine
variants).We found that none of these 11 variants segregated
with the disease in the family (data not shown).
The p.Ala201Val variant of CD7 was completely cose-
gregated with the disease in the psoriasis family. The normal
controls carrying this variation also show symptoms of allergy
or skin disease. However, this variation does not affect either
CD7 expression on T and NK cells or the costimulatory
activity of CD7 by comparing PBMCs of patients and controls.
This may be due to the fact that the amino-acid change from
alanine to valine seems to be conservative and non-
deleterious. The p.Ala201Val variant lies in the predicted
transmembrane domain of the CD7 molecule and may not
affect the structure and function of the transmembrane
domain on the CD7 molecule. We have also constructed
stable transfectants from a CD7-negative T cell line, H9, with
the normal or mutant CD7 gene integrated in the chromosome
by retrovirus. The stable transfectants were used to further
examine the CD7 expression, costimulatory activity, and
galectin-1-mediated death through CD7, because the binding
of extracellular galectin-1 and galectin-3 to CD7 induced
apoptosis in T cells (CD7, CD43, and CD45 as galectin-1
receptors, whereas CD7 and CD29 as galectin-3 receptors)
(Pace et al., 1999; Fukumori et al., 2003; Elola et al., 2005).
No significant change was found in the known function of
CD7 (data not shown). Our data, combined with the studies in
PBMCs from patients and controls (Figure 2), suggested that
CD7 is unlikely to be a disease-causing gene for psoriasis.
ZNF750, which encodes a putative C2H2 zinc-finger
protein, was first identified as the cause of seborrhea-like
dermatitis with psoriasiform elements in an Israeli Jewish
Moroccan family (Birnbaum et al., 2006). Hyperkeratosis of
skin over the elbows, knees, palms, and soles is evident, and
the affected members also present with seborrhea-like erythe-
matous rash on sebaceous follicle-rich areas. Affected members
carry a mutation (c.56_57dupCC) that causes a frameshift
leading to a truncated protein. Because the mutant transcript is
expressed in the keratinocytes of affected individuals and not in
the normal control, and also because affected individuals have
a high level of ZNF750 transcript, a dominant-negative model
was proposed. Although we identified ZNF750 as the putative
gene responsible for psoriasis in our five-generation family, our
study differs from that of Birnbaum et al. (2006) both in clinical
presentation and in molecular mechanism. First, although the
clinical manifestation in our psoriasis family varies from mild
lesions on the elbows and knees to the classical plaque over
most of the body surface, there is no associated seborrheic
dermatitis. Second, at the molecular levels, the mutation we
identified is a point mutation in the promoter region, which
decreases the promoter activity of ZNF750, thus suggesting a
haploinsufficiency model.
Attempting to measure the mRNA levels of ZNF750 in the
keratinocytes, where the gene is highly expressed, was not
possible because the family refused to participate in skin
biopsies. The ZNF750 transcripts in the Epstein–Barr virus-
transformed lymphoblastoid cells of patients and controls
were measured by TaqMan quantitative PCR with an Assay-
on-Demand kit from Applied Biosystems (Foster City, CA);
however, the levels of the transcripts were quite low in both
normal and patients’ cells with the Ct (threshold cycle) value
above 34 (data not shown), making the detection of any
significant difference unreliable.
The c.625A4C mutation of ZNF750 cosegregated with
the disease in the psoriasis family and decreased ZNF750
promoter activity, indicating the involvement of ZNF750 in
psoriasis susceptibility. EMSA data suggested that the
c.625A4C mutation causes an increase in repressor
binding to inhibit ZNF750 promoter activity and is likely to
involve the transcription factors ESE-1, ESE-2, and PU.1. It is
interesting to note that ESE-1 and ESE-2 are highly expressed
in epithelial cells. Further study will be needed to confirm the
role of the Ets family in the regulation of the ZNF750 gene
expression. The c.625A4C mutation was also found in
one of 85 sporadic psoriasis patients studied but not in 188
normal subjects; together, the mutation accounts for 1.7%
(CI: 0.2–5.84%) of the psoriasis in the Chinese population.
We have also attempted to investigate whether other
mutations in the ZNF750 gene play a role in the more
common form of psoriasis. Although we identified three
additional sequence variations (c.646G4A, c.597C4T,
and c. 1046T4C (p.Leu349Pro)), we did not know the
functional significance of these variants. Furthermore,
the study was limited because we did not fully sequence
the ZNF750 gene in controls, so most variants unique to
controls would have been missed. The impact of the ZNF750
gene in the common form of psoriasis remained to be
elucidated.
MATERIALS AND METHODS
Patients
A five-generation psoriasis kindred with apparent autosomal-
dominant inheritance was identified at the National Taiwan
University Hospital. This family comprised a total of 16 members
with classical psoriasis lesions, 10 with mild skin lesions, and 43
who were unaffected, as previously described (Hwu et al., 2005). In
addition, 35 independent familial psoriasis and 85 sporadic psoriasis
patients were recruited from the Chang Gung Memorial Hospital
(CGMH) Health System. Most of the psoriasis families were small
with only two members affected; however, eight of them had an
extended family with more than four members affected. All
individuals were examined by at least two dermatologists. As
controls, 188 healthy Chinese subjects were randomly selected from
the Taiwan Han Chinese Cell and Genome Bank (Pan et al., 2006).
The random Chinese controls and all participating patients were of
Han Chinese origin residing in Taiwan. The study was approved by
the National Taiwan University Hospital and CGMH institutional
review boards. Informed consent was obtained from each participant
for all studies in accordance with institutional requirements and the
Declaration of Helsinki Principles.
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Strategy to identify the disease-causal variants in the index
family
Our strategy was to use the classical positional cloning approach by
sequencing of candidate genes in the 3.8-Mb region on chromosome
17q to identify the disease-causing gene. Sequence variants present
in the proband (individual IV-5 in the five-generation family; Hwu
et al., 2005) but not in the normal control (not from this family) and
not found in the dbSNP databases were subjected to segregation
analysis, which consisted of sequencing all 23 affected members
(13 severely affected and 10 mildly affected) and 16 unaffected
members in the index family. We considered the disease-causal
variants to be segregated completely with the disease and should not
be present in normal controls. Functional studies were then carried
out to further characterize the mutation.
DNA sequence analysis
Genomic DNA was purified from peripheral blood using the
PUREGENE DNA purification kit (Gentra Systems, Minneapolis,
MN). For each candidate gene, we sequenced all exons, including
50 and 30 untranslated regions, intron–exon boundaries, and up to
1.2 kb of the promoter region. PCR primers were designed by the
Primer Z primer design program (http://140.109.54.18/primerz/
beginDesign.do) and the Primer 3 program (http://frodo.wi.mit.edu/
cgi-bin/primer3/primer3_www.cgi). The PCR products were purified
with enzymatic ExoI/SAP treatment (USB, Cleveland, OH) and then
sequenced using an ABI PRISM 3700 DNA Analyzer (Applied
Biosystems). Results were analyzed using Sequencher 4.6 software
(Gene Codes Corporation, Ann Arbor, MI), and the DNA sequences
obtained were compared to published sequences. Mutation nomen-
clature follows the journal guidelines (http://www.hgvs.org/
mutnomen) with the numbering using the A of the ATG translation
initiation codon in cDNA reference sequence as nucleotide þ 1.
Functional analysis of the CD7 gene
Flow cytometric analysis of CD7. PBMCs were isolated by
Ficoll–Paque (Amersham Pharmacia, Uppsala, Sweden) density
centrifugation from heparinized venous blood samples. Staining of
cells for three-color flow cytometry was performed. Briefly, 5 105
cells were suspended in 100 ml of phosphate-buffered saline
containing 0.1% sodium azide and 3% fetal calf serum and were
incubated with different fluorochrome-conjugated (FITC, phycoery-
thrin, or allophycocyanin (APC)) mAbs for 20minutes at 4 1C,
including CD3 (UCHT1), CD4 (RPA-T4), CD7 (M-T701), CD8 (RPA-
T8), and CD56 (B159) purchased from BD Pharmingen (San Diego,
CA). Appropriate fluorochrome-conjugated mAbs of the same
isotype were used as controls. The stained cells were washed three
times, fixed in 1% paraformaldehyde in phosphate-buffered saline,
and analyzed for immunofluorescence using a FACSCalibur flow
cytometer (Becton-Dickinson, San Jose, CA). The level of CD7
expression on CD4þ , CD8þ , and CD56þ subsets was determined
by multicolor staining followed by FACS analysis.
T-cell activation. Round-bottom 96-well plates were precoated
with 200 ml 10mgml1 anti-CD3 (UCHT1) and/or anti-CD7 mAb
(M-T701) in phosphate-buffered saline and incubated overnight at
4 1C. Purified PBMCs (2 105 per well) were cultured in RPMI 1640
plus 10% fetal bovine serum in a total volume of 200ml for 12, 24, 48,
and 72hours. After culture, the culture supernatant were collected
and analyzed for TNF-a and IFN-g using specific capture ELISA kits
(BD Pharmingen), according to the manufacturer’s description. The
standard curve of each cytokine was performed using a known
concentration of recombinant cytokines. For proliferation assays, cells
were cultured in plates coated with anti-CD3 and/or anti-CD7 for
24hours and then pulsed with 1mCi 3H-thymidine (Perkin Elmer Life
Inc., Boston, MA) for another 16hours. The cells were harvested and
the incorporation of 3H-thymidine was measured on a TopCount
Microplate Scintillation Counter (Packard, Meriden, CT).
Functional promoter analysis of ZNF750 gene
Transcription factor binding site identification. The promoter
region of ZNF750 was analyzed with TFSEARCH and MOTIF Search
programs based on TransFac database to predict the binding site of
transcription factors.
Reporter constructs. The ZNF750 cDNA reference sequence was
derived from GenBank, NM_024702.2. The ZNF750 promoter
sequence was retrieved from the genomic reference sequence with
GenBank accession number NT_010663.14. All promoter poly-
morphisms numbering follows the journal guidelines (http://
www.hgvs.org/mutnomen) using þ 1 as the A of the ATG translation
initiation codon. An approximately 0.87-kb fragment (841 to þ 31)
containing the promoter region of the ZNF750 was amplified from
human genomic DNA and cloned into the pGEM-T Easy vector
(Promega, Madison, WI) (Table S1). The C allele of c.625A4C
variant was introduced into the promoter region using site-directed
mutagenesis with recombinant PCR method (Ansaldi et al., 1996).
These normal and mutated fragments were then released from the
pGEM-T Easy vector and subcloned into the upstream region of the
firefly luciferase gene of the pGL3-basic vector (Promega). All
constructs were subjected to nucleotide sequencing to confirm their
correct sequence and orientation.
Transient transfection and luciferase assay. Human keratino-
cyte cell line, HaCaT, was kindly provided by Dr Te-Chang Lee
(Academia Sinica, Taipei, Taiwan) with permission from Dr
NE Fusenig (German Cancer Research Center, Heidelberg, Germany).
HaCaT cells were grown in DMEM and 10% fetal bovine serum
supplemented with 100Uml1 penicillin, 100mgml1 streptomy-
cin, and 2mM L-glutamine. A total of 2 104 cells were seeded in
each well of a 24-well plate and transfected with 480 ng of each
reporter construct along with 16 ng of pRL-TK vector (Promega)
containing the Renilla luciferase gene as an indicator for normal-
ization of transfection efficiency. Transfections were performed by
using FuGENE HD (Roche Applied Science, Indianapolis, IN),
according to the manufacturer’s instructions. Cells were incubated
for 48 hours and analyzed for luciferase activity with the Dual-
Luciferase Assay System (Promega). Firefly luminescence was
normalized to Renilla luminescence and reported as relative
luciferase units. All experiments were performed in triplicate and
independently performed at least three times.
Electrophoretic mobility shift assay. Nuclear extracts from
human HaCaT cells were prepared using the Nuclear Extract Kit
(Active Motif, Carlsbad, CA), according to the manufacturer’s
instructions. Oligonucleotides were synthesized and biotin-labeled
using the Biotin 30 End DNA Labeling Kit (Pierce Biotechnology,
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Rockford, IL). The sequence of the biotin-labeled probes are as
follows: N1 50-TGCTCAAGTTCTAAAGGAAAGTCTCACATG-30 and
M1 50-TGCTCAAGTTCTAACGGAAAGTCTCACATG-30. We incu-
bated HaCaT cell nuclear extract and biotin-labeled double-strand
oligonucleotide using a non-radioactive LightShift Chemilumines-
cent EMSA Kit (Pierce Biotechnology). The reaction was carried out
with 5 mg nuclear proteins and 1 mg of poly(dI-dC) at 25 1C for
20minutes. For competition studies, we incubated a 5- to 100-fold
excess of unlabeled oligonucleotides (29–30 bp in length) with the
nuclear extract before adding the biotin-labeled oligonucleotide.
The protein–DNA complexes were separated from unbound DNA
on a non-denaturing 8% polyacrylamide gel and transferred onto a
nitrocellulose membrane. We detected the signal with LightShift
Chemiluminescent EMSA Kit (Pierce Biotechnology), according to
the manufacturer’s instructions. The sequences of oligonucleotides
containing consensus binding sites for transcription factors for
competition studies were listed in Table S1.
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